• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生长激素受体 (GHR)-信号对肝糖酵解、从头脂肪生成和胰岛素敏感性的直接和系统作用,与脂肪变性有关。

Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis.

机构信息

Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, IL, United States of America; Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, United States of America.

Department of Biology & Bioinformatics Program, Boston University, Boston, MA, United States of America.

出版信息

Metabolism. 2023 Jul;144:155589. doi: 10.1016/j.metabol.2023.155589. Epub 2023 May 13.

DOI:10.1016/j.metabol.2023.155589
PMID:37182789
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10843389/
Abstract

BACKGROUND

Evidence is accumulating that growth hormone (GH) protects against the development of steatosis and progression of non-alcoholic fatty liver disease (NAFLD). GH may control steatosis indirectly by altering systemic insulin sensitivity and substrate delivery to the liver and/or by the direct actions of GH on hepatocyte function.

APPROACH

To better define the hepatocyte-specific role of GH receptor (GHR) signaling on regulating steatosis, we used a mouse model with adult-onset, hepatocyte-specific GHR knockdown (aHepGHRkd). To prevent the reduction in circulating insulin-like growth factor 1 (IGF1) and the subsequent increase in GH observed after aHepGHRkd, subsets of aHepGHRkd mice were treated with adeno-associated viral vectors (AAV) driving hepatocyte-specific expression of IGF1 or a constitutively active form of STAT5b (STAT5b). The impact of hepatocyte-specific modulation of GHR, IGF1 and STAT5b on carbohydrate and lipid metabolism was studied across multiple nutritional states and in the context of hyperinsulinemic:euglycemic clamps.

RESULTS

Chow-fed male aHepGHRkd mice developed steatosis associated with an increase in hepatic glucokinase (GCK) and ketohexokinase (KHK) expression and de novo lipogenesis (DNL) rate, in the post-absorptive state and in response to refeeding after an overnight fast. The aHepGHRkd-associated increase in hepatic KHK, but not GCK and steatosis, was dependent on hepatocyte expression of carbohydrate response element binding protein (ChREBP), in re-fed mice. Interestingly, under clamp conditions, aHepGHRkd also increased the rate of DNL and expression of GCK and KHK, but impaired insulin-mediated suppression of hepatic glucose production, without altering plasma NEFA levels. These effects were normalized with AAV-mediated hepatocyte expression of IGF1 or STAT5b. Comparison of the impact of AAV-mediated hepatocyte IGF1 versus STAT5b in aHepGHRkd mice across multiple nutritional states, indicated the restorative actions of IGF1 are indirect, by improving systemic insulin sensitivity, independent of changes in the liver transcriptome. In contrast, the actions of STAT5b are due to the combined effects of raising IGF1 and direct alterations in the hepatocyte gene program that may involve suppression of BCL6 and FOXO1 activity. However, the direct and IGF1-dependent actions of STAT5b cannot fully account for enhanced GCK activity and lipogenic gene expression observed after aHepGHRkd, suggesting other GHR-mediated signals are involved.

CONCLUSION

These studies demonstrate hepatocyte GHR-signaling controls hepatic glycolysis, DNL, steatosis and hepatic insulin sensitivity indirectly (via IGF1) and directly (via STAT5b). The relative contribution of these indirect and direct actions of GH on hepatocytes is modified by insulin and nutrient availability. These results improve our understanding of the physiologic actions of GH on regulating adult metabolism to protect against NAFLD progression.

摘要

背景

越来越多的证据表明,生长激素 (GH) 可预防脂肪变性的发展和非酒精性脂肪性肝病 (NAFLD) 的进展。GH 可能通过改变全身胰岛素敏感性和向肝脏输送底物,或者通过 GH 对肝细胞功能的直接作用,间接控制脂肪变性。

方法

为了更好地定义 GH 受体 (GHR) 信号在调节脂肪变性中的肝细胞特异性作用,我们使用了一种成年后肝细胞特异性 GHR 敲低 (aHepGHRkd) 的小鼠模型。为了防止 aHepGHRkd 后观察到的循环胰岛素样生长因子 1 (IGF1) 减少和随后 GH 增加,aHepGHRkd 小鼠的亚组用腺相关病毒载体 (AAV) 治疗,该载体驱动 IGF1 或组成型激活形式的 STAT5b (STAT5b) 在肝细胞中的特异性表达。研究了肝细胞特异性调节 GHR、IGF1 和 STAT5b 对碳水化合物和脂质代谢的影响,跨越多种营养状态,并在高胰岛素-正常血糖夹闭的背景下进行。

结果

在 Chow 喂养的雄性 aHepGHRkd 小鼠中,在吸收后状态下和在隔夜禁食后重新喂养时,观察到与肝葡糖激酶 (GCK) 和酮己糖激酶 (KHK) 表达和从头脂肪生成 (DNL) 率增加相关的脂肪变性。aHepGHRkd 相关的肝 KHK 增加,但不是 GCK 和脂肪变性,依赖于再喂养小鼠中肝碳水化合物反应元件结合蛋白 (ChREBP) 的肝细胞表达。有趣的是,在夹闭条件下,aHepGHRkd 还增加了 DNL 以及 GCK 和 KHK 的表达,但损害了胰岛素介导的肝葡萄糖产生抑制,而不改变血浆 NEFA 水平。这些影响通过 AAV 介导的 IGF1 或 STAT5b 在肝细胞中的表达得到了正常化。在多种营养状态下比较 AAV 介导的 IGF1 与 STAT5b 在 aHepGHRkd 小鼠中的影响表明,IGF1 的恢复作用是间接的,通过改善全身胰岛素敏感性,而不改变肝转录组。相比之下,STAT5b 的作用归因于提高 IGF1 和直接改变肝细胞基因程序的联合作用,这可能涉及 BCL6 和 FOXO1 活性的抑制。然而,STAT5b 的直接和 IGF1 依赖性作用不能完全解释 aHepGHRkd 后观察到的 GCK 活性和脂肪生成基因表达的增强,表明还涉及其他 GHR 介导的信号。

结论

这些研究表明,肝细胞 GHR 信号间接(通过 IGF1)和直接(通过 STAT5b)控制肝糖酵解、DNL、脂肪变性和肝胰岛素敏感性。GH 对肝细胞的这些间接和直接作用的相对贡献受胰岛素和营养供应的调节。这些结果提高了我们对 GH 调节成年代谢以预防 NAFLD 进展的生理作用的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/567d49eb2611/nihms-1955805-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/38dc7a835205/nihms-1955805-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/b299e1d8f678/nihms-1955805-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/5bd8d4003953/nihms-1955805-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/567d49eb2611/nihms-1955805-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/38dc7a835205/nihms-1955805-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/b299e1d8f678/nihms-1955805-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/5bd8d4003953/nihms-1955805-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6d5/10843389/567d49eb2611/nihms-1955805-f0004.jpg

相似文献

1
Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis.生长激素受体 (GHR)-信号对肝糖酵解、从头脂肪生成和胰岛素敏感性的直接和系统作用,与脂肪变性有关。
Metabolism. 2023 Jul;144:155589. doi: 10.1016/j.metabol.2023.155589. Epub 2023 May 13.
2
GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner.生长激素以性别依赖和 IGF1 独立的方式直接抑制脂肪变性和肝损伤。
J Endocrinol. 2021 Jan;248(1):31-44. doi: 10.1530/JOE-20-0326.
3
Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice.生长激素抑制成年小鼠肝脏从头脂肪生成
Diabetes. 2015 Sep;64(9):3093-103. doi: 10.2337/db15-0370. Epub 2015 May 26.
4
Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction.成年期肝细胞生长激素抵抗促进雄性小鼠非酒精性脂肪性肝炎,而无严重的全身代谢功能障碍。
Endocrinology. 2018 Nov 1;159(11):3761-3774. doi: 10.1210/en.2018-00669.
5
Growth Hormone Control of Hepatic Lipid Metabolism.生长激素对肝脏脂质代谢的调控
Diabetes. 2016 Dec;65(12):3598-3609. doi: 10.2337/db16-0649. Epub 2016 Sep 27.
6
Hepatic PPARγ Is Not Essential for the Rapid Development of Steatosis After Loss of Hepatic GH Signaling, in Adult Male Mice.在成年雄性小鼠中,肝脏PPARγ对于肝脏生长激素信号缺失后脂肪变性的快速发展并非必不可少。
Endocrinology. 2016 May;157(5):1728-35. doi: 10.1210/en.2015-2077. Epub 2016 Mar 7.
7
Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.肝细胞中的 Tcf7l2 调控饮食诱导的非酒精性脂肪性肝病小鼠模型中的从头脂肪生成。
Diabetologia. 2023 May;66(5):931-954. doi: 10.1007/s00125-023-05878-8. Epub 2023 Feb 10.
8
Towards Understanding the Direct and Indirect Actions of Growth Hormone in Controlling Hepatocyte Carbohydrate and Lipid Metabolism.探讨生长激素调控肝细胞糖脂代谢的直接和间接作用。
Cells. 2021 Sep 24;10(10):2532. doi: 10.3390/cells10102532.
9
Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism.肝脏特异性缺失生长激素受体揭示了生长激素信号在肝脏脂质代谢中的重要作用。
J Biol Chem. 2009 Jul 24;284(30):19937-44. doi: 10.1074/jbc.M109.014308. Epub 2009 May 21.
10
Metabolic effects of reduced growth hormone action in fatty liver disease.生长激素作用降低对脂肪肝疾病的代谢影响。
Hepatol Int. 2018 Sep;12(5):474-481. doi: 10.1007/s12072-018-9893-7. Epub 2018 Sep 11.

引用本文的文献

1
Association of IGF-1 and IGFBP-3 with metabolic abnormalities among children and adolescents.儿童和青少年中胰岛素样生长因子-1(IGF-1)及胰岛素样生长因子结合蛋白-3(IGFBP-3)与代谢异常的关联
Front Endocrinol (Lausanne). 2025 Jun 5;16:1579107. doi: 10.3389/fendo.2025.1579107. eCollection 2025.
2
Development of human growth hormone-treated chimeric mice with humanized livers for an evaluation model of drug-induced fatty liver disease.利用人源化肝脏的生长激素处理嵌合小鼠建立药物性脂肪性肝病评估模型
Arch Toxicol. 2025 May;99(5):2133-2142. doi: 10.1007/s00204-025-03986-5. Epub 2025 Feb 21.
3
Current views on etiology, diagnosis, epidemiology and gene therapy of maturity onset diabetes in the young.

本文引用的文献

1
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.超重和肥胖人群中非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球患病率:一项系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.
2
A modest change in housing temperature alters whole body energy expenditure and adipocyte thermogenic capacity in mice.住房温度的适度变化会改变小鼠的全身能量消耗和脂肪细胞的产热能力。
Am J Physiol Endocrinol Metab. 2022 Dec 1;323(6):E517-E528. doi: 10.1152/ajpendo.00079.2022. Epub 2022 Nov 9.
3
关于青年发病型成年糖尿病的病因、诊断、流行病学及基因治疗的当前观点。
Front Endocrinol (Lausanne). 2025 Jan 20;15:1497298. doi: 10.3389/fendo.2024.1497298. eCollection 2024.
4
Growth hormone receptor in VGLUT2 or Sim1 cells regulates glycemia and insulin sensitivity.VGLUT2或Sim1细胞中的生长激素受体调节血糖和胰岛素敏感性。
Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2407225121. doi: 10.1073/pnas.2407225121. Epub 2024 Dec 19.
5
High-coverage targeted lipidomics revealed a novel serum lipid dysregulation profile in adult growth hormone deficiency.高覆盖靶向脂质组学揭示了成人生长激素缺乏症患者新的血清脂质失调特征。
Endocr Connect. 2024 Dec 20;14(1). doi: 10.1530/EC-24-0424. Print 2025 Jan 1.
6
LCoRL Regulates Growth and Metabolism.LCoRL 调节生长和代谢。
Endocrinology. 2024 Oct 30;165(12). doi: 10.1210/endocr/bqae146.
7
Liver-specific actions of GH and IGF1 that protect against MASLD.生长激素(GH)和胰岛素样生长因子1(IGF1)的肝脏特异性作用可预防代谢相关脂肪性肝病(MASLD)。
Nat Rev Endocrinol. 2025 Feb;21(2):105-117. doi: 10.1038/s41574-024-01037-0. Epub 2024 Sep 25.
8
Immunisation of the somatostatin gene alters hypothalamic-pituitary-liver gene expressions and enhances growth in Dazu black goats.生长抑素基因免疫改变大足黑山羊下丘脑-垂体-肝脏基因表达并促进生长
Anim Biosci. 2024 Nov;37(11):1987-1999. doi: 10.5713/ab.24.0121. Epub 2024 Jun 26.
9
Modifications of the GH Axis Reveal Unique Sexually Dimorphic Liver Signatures for , , , , .生长激素轴的改变揭示了针对……的独特性别二态性肝脏特征。
J Endocr Soc. 2024 Jan 31;8(3):bvae015. doi: 10.1210/jendso/bvae015. eCollection 2024 Jan 16.
An evolutionary trade-off between host immunity and metabolism drives fatty liver in male mice.
宿主免疫与代谢之间的进化权衡导致雄性小鼠发生脂肪肝。
Science. 2022 Oct 21;378(6617):290-295. doi: 10.1126/science.abn9886. Epub 2022 Oct 20.
4
Sex matters in liver fat regulation.性别在肝脂肪调节中起重要作用。
Science. 2022 Oct 21;378(6617):252-253. doi: 10.1126/science.ade7614. Epub 2022 Oct 20.
5
The GH/IGF-1 Axis Is Associated With Intrahepatic Lipid Content and Hepatocellular Damage in Overweight/Obesity.生长激素/胰岛素样生长因子 1 轴与超重/肥胖患者肝内脂质含量和肝细胞损伤有关。
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3624-e3632. doi: 10.1210/clinem/dgac405.
6
Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data.使用 MetaboAnalyst 5.0 进行 LC-HRMS 光谱处理、多组学整合和全局代谢组学数据的协变量调整。
Nat Protoc. 2022 Aug;17(8):1735-1761. doi: 10.1038/s41596-022-00710-w. Epub 2022 Jun 17.
7
Interplay Between GH-regulated, Sex-biased Liver Transcriptome and Hepatic Zonation Revealed by Single-Nucleus RNA Sequencing.基于单细胞 RNA 测序的 GH 调控、性别偏向性肝转录组及其肝区带相互作用研究。
Endocrinology. 2022 Jul 1;163(7). doi: 10.1210/endocr/bqac059.
8
Constitutively Active STAT5b Feminizes Mouse Liver Gene Expression.组成性激活的 STAT5b 使小鼠肝脏基因表达雌性化。
Endocrinology. 2022 May 1;163(5). doi: 10.1210/endocr/bqac046.
9
Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.生长激素和胰岛素样生长因子 1 对非酒精性脂肪性肝病的调控。
J Clin Endocrinol Metab. 2022 Jun 16;107(7):1812-1824. doi: 10.1210/clinem/dgac088.
10
Towards Understanding the Direct and Indirect Actions of Growth Hormone in Controlling Hepatocyte Carbohydrate and Lipid Metabolism.探讨生长激素调控肝细胞糖脂代谢的直接和间接作用。
Cells. 2021 Sep 24;10(10):2532. doi: 10.3390/cells10102532.